Abstract: Described here are genetically modified microorganisms with reduced protease activity for the expression of recombinant proteins and without mucoid phenotypes. Also described are methods of making and using the same.
Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
Type:
Grant
Filed:
August 11, 2023
Date of Patent:
January 14, 2025
Assignee:
ModernaTX, Inc.
Inventors:
Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
Abstract: Provided herein are genetically modified microorganisms comprising a nonsense mutation in a gene encoding an efflux pump or import protein, and a vector encoding a suppressor tRNA that enables translation of the efflux pump or import protein, mitigating the effect of the nonsense mutation. Also provided are methods of producing a vector or markerless DNA using the genetically modified microorganisms provided herein.
Type:
Application
Filed:
October 17, 2022
Publication date:
January 9, 2025
Applicant:
ModernaTX, Inc.
Inventors:
Kevin Smith, Joe R. Sarkis, Stoil Dimitrov
Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
Type:
Application
Filed:
August 12, 2024
Publication date:
December 12, 2024
Applicant:
ModernaTX, INC.
Inventors:
Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
Type:
Application
Filed:
August 12, 2024
Publication date:
December 5, 2024
Applicant:
ModernaTX, INC.
Inventors:
Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
Type:
Application
Filed:
February 28, 2022
Publication date:
December 5, 2024
Applicant:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
Type:
Application
Filed:
August 12, 2024
Publication date:
November 28, 2024
Applicant:
ModernaTX, INC.
Inventors:
Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Type:
Grant
Filed:
September 14, 2023
Date of Patent:
November 26, 2024
Assignee:
ModernaTX, Inc.
Inventors:
Kerry E. Benenato, Mark Cornebise, Ellalahewage Sathyajith Kumarasinghe
Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
Type:
Grant
Filed:
July 29, 2016
Date of Patent:
November 26, 2024
Assignee:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Eric Yi-Chun Huang, Nicholas Valiante, Tal Zaks
Abstract: The present disclosure in part provides compounds (i.e., PEG lipids) which are useful in pharmaceutical compositions, cosmetic compositions, and drug delivery systems, e.g, for use in lipid nanoparticle (LNP) formulations. The present disclosure also provides LNP formulations comprising PEG lipids described herein, and methods of using the same. For example, the LNPs provided herein are useful for the delivery of an agent (e.g, therapeutic agent) to a subject. The PEG lipids and LNPs provided herein, in certain embodiments, exhibit increased PEG shedding compared to existing PEG lipids and LNP formulations.
Abstract: The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Abstract: The disclosure features a lipid nanoparticle (LNP) formulation comprising a plurality of LNPs and a stabilizing agent that mitigates the degradation of the LNPs or a subpopulation thereof. Lipid nanoparticles further including therapeutics and/or prophylactics such as RNA are useful in the delivery of therapeutics and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. Methods of manufacturing LNP formulations and screening for a stabilizing agent are also disclosed.
Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
Type:
Application
Filed:
April 15, 2024
Publication date:
November 7, 2024
Applicant:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
Abstract: Described herein are methods of purifying nucleic acids (e.g., mRNAs) from feed solutions using continuous, multicolumn chromatography approaches. Also described are methods of increasing the efficiency of chromatography methods by performing purification methods in parallel using multiple columns.
Type:
Application
Filed:
August 12, 2022
Publication date:
November 7, 2024
Applicant:
ModernaTX, inc.
Inventors:
Mark Geng, Jason Murphy, Lei ZHOU, James Sinoimeri, Tahir Kapoor, Joseph Elich
Abstract: The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.